Merrill puts Martek at neutral

Martek Biosciences Corp. was rated at neutral by Merrill Lynch analyst David Munno neutral, with no significant catalyst to boost the stock in the near-term. The company had a disappointing third-quarter report and forward guidance, according to Munno. The negative news on poor earnings outlook is already priced into the stock. The Street consensus was lowered for 2007 and 2008 on third-quarter earnings per share. Shares of the Columbia, Md.-based pharmaceutical company were up 77 cents, or 3.53%, at $22.57. (Nasdaq: MATK)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.